Scientists uncover how tobacco rewires head and neck cancer metabolism through a single mucin molecule

Tobacco smoke has long been recognized as the dominant driver of the hardest-to-treat head and neck cancers, but the precise molecular machinery that converts chronic carcinogen exposure into aggressive, immune-resistant tumors has remained frustratingly opaque. Now a team at Emory University’s Winship Cancer Institute has traced that machinery to a single, unexpected culprit: MUC5B, a gel-forming mucin protein better known for its role in protective mucus layers than in cancer biology. In a study published in the Journal of Experimental & Clinical Cancer Research, the researchers show that tobacco carcinogens dismantle a genetic brake on MUC5B production, and that the resulting flood of this mucin reprograms tumor metabolism while systematically disarming the immune cells that would otherwise destroy the cancer. The finding, arrived at through a combination of multi-cohort genomics, single-cell sequencing, artificial intelligence-assisted tissue imaging, and mouse experiments, points to MUC5B as a potential therapeutic target in smoking-associated head and neck squamous cell carcinoma, or HNSCC.

The clinical stakes are considerable. Head and neck squamous cell carcinoma is broadly divided into two etiological camps: tumors driven by human papillomavirus, which tend to respond relatively well to treatment, and HPV-unrelated tumors, which are overwhelmingly linked to tobacco exposure and carry markedly worse outcomes. Understanding why smoking-associated tumors behave so aggressively has been a central unsolved question in the field. The Emory team, led by corresponding author Yong Teng, with Fan Yang, Fanghui Chen and Xinyu Cui as co-first authors, approached the problem by mining transcriptomic data across multiple patient cohorts, including The Cancer Genome Atlas, to identify genes whose activity tracks with tobacco exposure in HPV-unrelated HNSCC. Among the smoking-associated targets that emerged, MUC5B stood out as an immunomodulatory mucin whose elevated expression correlated with tumor progression.

To understand what MUC5B was actually doing inside tumors, the researchers turned to single-cell RNA sequencing, a technique that reads out gene activity in individual cells rather than in bulk tissue. This cell-type-resolved view revealed that high MUC5B levels were associated with a profound metabolic shift: tumor cells appeared to pivot toward enhanced fatty acid utilization, ramping up the machinery for fatty acid oxidation as a fuel source. Metabolic reprogramming of this kind is a hallmark of aggressive cancers, because rewired energy production can support rapid proliferation, survival under stress, and resistance to therapy. The team confirmed these metabolic signatures using gene set enrichment and gene set variation analyses, standard bioinformatic methods that test whether defined biological pathways are systematically activated or suppressed across samples.

The metabolic story was only half the picture. When the researchers characterized the tumor immune microenvironment, using both conventional analyses and a platform called GigaTIME to generate virtual multiplex immunofluorescence images, they found that MUC5B-high tumors harbored a distinctly immunosuppressive landscape. Macrophages, the immune cells that normally engulf threats and coordinate inflammatory responses, had been polarized toward an M2-like state, a wound-healing, tumor-tolerant phenotype that actively supports cancer growth. At the same time, infiltrating CD8-positive T cells, the cytotoxic soldiers responsible for killing tumor cells, were diminished. In effect, elevated MUC5B coincided with a double blow to anti-tumor immunity: the cancer’s metabolic engine was refitted for fatty acids, and the immune system’s assault force was simultaneously depleted and redirected.

Having established the correlation, the team went hunting for the upstream regulator that connects tobacco smoke to MUC5B in the first place. The answer lay with GATA4, a transcription factor that the researchers found binds directly to the MUC5B promoter, the DNA region that controls the gene’s activity, and represses its transcription. Under normal conditions, GATA4 acts as a molecular brake, keeping MUC5B production in check. But when the researchers exposed HNSCC cells to 4-nitroquinoline 1-oxide, or 4NQO, a carcinogen widely used to model tobacco-induced oral carcinogenesis, this regulatory axis broke down. 4NQO exposure reduced GATA4 expression and, critically, reduced GATA4’s occupancy of the MUC5B promoter, as demonstrated by chromatin immunoprecipitation experiments. With the brake released, MUC5B expression surged.

To test whether MUC5B was merely a bystander or an active orchestrator of these changes, the researchers silenced the gene in laboratory models and observed what happened. MUC5B silencing reversed the metabolic reprogramming, dialing back the fatty acid oxidation program, and restored a more favorable immune profile in cell-based assays. The decisive test came in animals: in immunocompetent mouse models of orthotopic tongue tumors exposed to 4NQO, silencing MUC5B reduced tumor growth. The use of immunocompetent mice is an important methodological detail, because it means the immune system was intact and functional during the experiments, allowing the team to observe genuine immune-mediated effects rather than artifacts of immunodeficient models. Together, the in vitro and in vivo data support a causal chain running from tobacco carcinogen, through GATA4 loss, through MUC5B induction, to metabolic rewiring and immune suppression.

The study’s architecture reflects a broader trend in modern cancer research, in which no single technique is sufficient to untangle a tumor’s complexity. The Emory group layered population-level transcriptomics on top of single-cell resolution, then added spatial context through AI-assisted immune profiling, and finally validated every computational observation with molecular assays, metabolic measurements, and functional immune cell experiments. The GigaTIME-based virtual multiplex immunofluorescence deserves particular note: by computationally reconstructing the spatial arrangement of immune and tumor cells within tissue, it allowed the team to quantify how MUC5B-high tumors organize their microenvironment, information that conventional single-marker staining cannot capture. This integration of artificial intelligence with traditional pathology is increasingly seen as essential for dissecting the tumor microenvironment, the dense ecosystem of cancer cells, immune cells, and supporting tissue that determines whether immunotherapy succeeds or fails.

Therapeutically, the implications are twofold. First, MUC5B itself becomes a candidate drug target, and the demonstration that its silencing reverses metabolic and immune alterations suggests that blocking this mucin, or restoring the GATA4-mediated repression that tobacco carcinogens erode, could resensitize smoking-associated tumors to immune attack. This matters because HPV-unrelated HNSCC patients currently face limited options and poor prognoses, and immunotherapies that work in other cancers often deliver disappointing results in this population, plausibly because the immunosuppressive microenvironment described in this study stands in the way. Second, the 4NQO/GATA4-MUC5B axis provides a mechanistic explanation for a long-standing clinical observation, namely that tobacco-exposed tumors are both more aggressive and more immune-evasive, and it does so through a defined molecular pathway rather than a vague appeal to mutational burden.

Caveats remain, as they always do in translational research. The work relied heavily on the 4NQO carcinogen as a proxy for tobacco exposure, a well-established but imperfect model of the far more complex chemical mixture in cigarette smoke. The mouse experiments, while conducted in immunocompetent animals and in an orthotopic setting that recapitulates the anatomical location of human disease, still require follow-up before MUC5B-targeting strategies reach the clinic. The authors also note that the published version was shared early as accepted peer-reviewed research, subject to final editorial production. Nonetheless, the study was supported by multiple NIH awards including R01DE033433 and R01DE033691, and the authors declare no competing interests. What the work delivers, with unusual clarity, is a complete mechanistic arc: a carcinogen, a transcriptional brake, a mucin, a metabolic switch, and an immune collapse, each link verified experimentally. For a disease in which tobacco’s fingerprints have been visible for decades without a matching molecular explanation, that arc is a genuine advance, and it reframes a humble mucus protein as a central node in one of oncology’s most stubborn problems.

Subject of Research: Tobacco-driven MUC5B regulation of metabolic reprogramming and immunosuppression in head and neck squamous cell carcinoma

Article Title: MUC5B orchestrates tobacco-driven metabolic rewiring and immunosuppression in head and neck squamous cell carcinoma

Article References: Yang, F., Chen, F., Cui, X., Yang, J., Steward-Tharp, S. M., Saba, N. F., & Teng, Y. (2026). MUC5B orchestrates tobacco-driven metabolic rewiring and immunosuppression in head and neck squamous cell carcinoma. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-026-03851-y

Image Credits: AI Generated

DOI: 10.1186/s13046-026-03851-y

Keywords: MUC5B, head and neck squamous cell carcinoma, tobacco, GATA4, 4NQO, metabolic reprogramming, fatty acid oxidation, immunosuppression, M2 macrophages, CD8 T cells, tumor microenvironment, single-cell sequencing